THERE’S CONFIDENCE IN BEING PREPARED

Get to know
ZEGALOGUE® (dasiglucagon) injection1

Be ZEGALOGUE-ready for the treatment of severe hypoglycemia1

ZEGALOGUE is indicated for the treatment of severe hypoglycemia in adults and children with diabetes aged 6 years and older.1

Rapid, reliable recovery when every minute counts1

In clinical trials, adult and pediatric patients with type 1 diabetes demonstrated recovery of plasma glucose levels with a single dose of ZEGALOGUE versus placebo1

Three randomized, double-blind, placebo-controlled, multicenter clinical trials in patients with type 1 diabetes: Trial A (N=170) and Trial B (N=45) were conducted in adults; Trial C (N=42) was conducted in patients aged 6-17. Primary endpoint: time to plasma glucose recovery (treatment success), defined as an increase in blood glucose of ≥20 mg/dL from time of administration of study drug, without additional intervention within 45 minutes. Please see full study design below.1*

SEE RESULTS

Available in an autoinjector or a prefilled syringe1

ZEGALOGUE® is prefilled with no reconstitution required.1

ABOUT THE DEVICES

First and only glucagon analog for the treatment of severe hypoglycemia1

ZEGALOGUE® offers product stability in an aqueous solution.1,2

LEARN MORE

    *The efficacy of ZEGALOGUE was demonstrated in 3 randomized, double-blind, placebo-controlled, multicenter clinical trials (Trials A, B, and C) in patients with type 1 diabetes. Trial A (N=170) and Trial B (N=45) were conducted in adult patients. Trial C (N=42) was conducted in patients aged 6-17 years. In all 3 trials, patients were randomized to receive subcutaneous doses of either ZEGALOGUE 0.6 mg, placebo, or (in Trials A and C) glucagon for injection 1.0 mg following controlled insulin-induced hypoglycemia. The primary endpoint for all 3 trials was time to plasma glucose recovery (treatment success), defined as an increase in blood glucose of ≥20 mg/dL from time of administration of study drug, without additional intervention within 45 minutes. Secondary endpoints included assessments of plasma glucose recovery at multiple time points following ZEGALOGUE injection. The primary hypothesis test was superiority of ZEGALOGUE versus placebo.1

    INDICATION
    INDICATION AND IMPORTANT SAFETY INFORMATION

    ZEGALOGUE (dasiglucagon) injection is indicated for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes aged 6 years and above.

    IMPORTANT SAFETY INFORMATION
    Contraindications

    ZEGALOGUE is contraindicated in patients with pheochromocytoma because of the risk of substantial increase in blood pressure and in patients with insulinoma because of the risk of hypoglycemia.

    plus icon
    minus icon
    INDICATION

    ZEGALOGUE (dasiglucagon) injection is indicated for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes aged 6 years and above.

    IMPORTANT SAFETY INFORMATION

    Contraindications

    ZEGALOGUE is contraindicated in patients with pheochromocytoma because of the risk of substantial increase in blood pressure and in patients with insulinoma because of the risk of hypoglycemia.

    Warnings and Precautions

    ZEGALOGUE is contraindicated in patients with pheochromocytoma because glucagon products may stimulate the release of catecholamines from the tumor. If the patient develops a substantial increase in blood pressure and a previously undiagnosed pheochromocytoma is suspected, 5 to 10 mg of phentolamine mesylate, administered intravenously, has been shown to be effective in lowering blood pressure.

    In patients with insulinoma, administration of glucagon products may produce an initial increase in blood glucose; however, ZEGALOGUE administration may directly or indirectly (through an initial rise in blood glucose) stimulate exaggerated insulin release from an insulinoma and cause hypoglycemia. ZEGALOGUE is contraindicated in patients with insulinoma. If a patient develops symptoms of hypoglycemia after a dose of ZEGALOGUE, give glucose orally or intravenously.

    Allergic reactions have been reported with glucagon products; these include generalized rash, and in some cases anaphylactic shock with breathing difficulties and hypotension. Advise patients to seek immediate medical attention if they experience any symptoms of serious hypersensitivity reactions.

    ZEGALOGUE is effective in treating hypoglycemia only if sufficient hepatic glycogen is present. Patients in states of starvation, with adrenal insufficiency or chronic hypoglycemia may not have adequate levels of hepatic glycogen for ZEGALOGUE administration to be effective. Patients with these conditions should be treated with glucose.

    Adverse Reactions 

    The most common adverse reactions (≥2%) associated with ZEGALOGUE in adults were nausea, vomiting, headache, diarrhea and injection site pain; in pediatrics: nausea, vomiting, headache and injection site pain.

    Drug Interactions

    Patients taking beta-blockers may have a transient increase in pulse and blood pressure when given ZEGALOGUE. In patients taking indomethacin, ZEGALOGUE may lose its ability to raise blood glucose or may produce hypoglycemia. ZEGALOGUE may increase the anticoagulant effect of warfarin.

    Please see Full Prescribing Information.

    References: 1. Zegalogue (dasiglucagon). Prescribing information. Zealand Pharma A/S; April 2021. 2. Hövelmann U, Bysted BV, Mouritzen U, et al. Pharmacokinetic and pharmacodynamic characteristics of dasiglucagon, a novel soluble and stable glucagon analog. Diabetes Care. 2018;41(3):531-537. doi:10.2337/dc17-1402

    References: 1. International Hypoglycaemia Study Group. Minimizing hypoglycemia in diabetes. Diabetes Care. 2015;38(8):1583-1591. doi:10.2337/dc15-0279 2. Edridge CL, Dunkley AJ, Bodicoat DH, et al. Prevalence and incidence of hypoglycaemia in 532,542 people with type 2 diabetes on oral therapies and insulin: a systematic review and meta-analysis of population based studies. PLoS One. 2015;10(6):e0126427. doi:10.1371/journal.pone.0126427 3. American Diabetes Association. 6. Glycemic targets: Standards of Medical Care in Diabetes—2021. Diabetes Care. 2021;44(suppl 1):S73-S84. doi:10.2337/dc21-S006 4. American Diabetes Association. 6. Glycemic targets: Standards of Medical Care in Diabetes—2020. Diabetes Care. 2020;43(suppl 1):S66-S76. doi:10.2337/dc20-S006

    References: 1. American Diabetes Association. 6. Glycemic targets: Standards of Medical Care in Diabetes—2021. Diabetes Care. 2021;44(suppl 1):S73-S84. doi:10.2337/dc21-S006 2. Cobb E, Watson N, Wardian J, Morrow C, Sauerwein T. Glucagon kits: are your patients prepared for a hypoglycemic emergency? AADE in Practice. 2017;5(1):12-17. doi:10.1177/2325160316677575 3. International Hypoglycaemia Study Group. Minimizing hypoglycemia in diabetes. Diabetes Care. 2015;38(8):1583-1591. doi:10.2337/dc15-0279 4. Zegalogue (dasiglucagon). Prescribing information. Zealand Pharma A/S; April 2021.

    References: 1. Zegalogue (dasiglucagon). Prescribing information. Zealand Pharma A/S; April 2021. 2. Pieber TR, Aronson R, Hövelmann U, et al. Dasiglucagon: a next-generation glucagon analog for rapid and effective treatment of severe hypoglycemia: results of phase 3 randomized double-blind clinical trial. Diabetes Care. Preprint posted online April 21, 2021. doi:10.2337/DC20-2995 3. Data on file. Zealand Pharma A/S; 2021.

    References: 1. Zegalogue (dasiglucagon). Prescribing information. Zealand Pharma A/S; April 2021. 2. Battelino T, Tehranchi R, Bailey T, et al. Dasiglucagon, a next-generation ready-to-use glucagon analog, for treatment of severe hypoglycemia in children and adolescents with type 1 diabetes: results of a phase 3, randomized controlled trial. Pediatr Diabetes. Preprint posted online May 2, 2021. doi:10.1111/pedi.13220

    Reference: Zegalogue (dasiglucagon). Prescribing information. Zealand Pharma A/S; April 2021.

    References: 1. Zegalogue (dasiglucagon). Prescribing information. Zealand Pharma A/S; April 2021. 2. U.S. Food and Drug Administration, Center for Drug Evaluation and Research. ZEGALOGUE NDA 214231 approval letter, March 22, 2021. Accessed March 26, 2021. https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2021/214231Orig1s000ltr.pdf

    References: 1. Zegalogue (dasiglucagon). Prescribing information. Zealand Pharma A/S; April 2021. 2. Hövelmann U, Bysted BV, Mouritzen U, et al. Pharmacokinetic and pharmacodynamic characteristics of dasiglucagon, a novel soluble and stable glucagon analog. Diabetes Care. 2018;41(3):531-537. doi:10.2337/dc17-1402 3. Macchi F, Wenander C, Lundholt BK. Dasiglucagon is a novel stable glucagon analog with fast glucose response following subcutaneous injection in hypoglycemic rats. Poster presented at: Virtual European Association for the Study of Diabetes Annual Meeting 2020; September 21-25, 2020.

    close button
    ZEGALOGUE® vertical logo

    Are you a healthcare professional?

    The information in this section of the website is intended for US healthcare professionals only.

    YES
    NO

    Zegalogue.com is currently changing ownership to Novo Nordisk Inc. so parties referenced throughout will soon be different. Stay tuned for an updated Zegalogue.com, including a revised Privacy Policy and Terms of Use, as soon as we complete the final conversion. For any additional questions, please see the links below.

    Press Release
    Continue to zegalogue.com
    Visit novonordisk-us.com
    ZEGALOGUE® vertical logo

    Are you ready to leave?

    You are now leaving ZEGALOGUE.com/hcp.

    By clicking the “Continue” button below, you will be taken to a website that may contain links or references to other websites in which our privacy policy may not apply. We encourage you to read the privacy policy of every website you visit. By clicking the “No thanks” button below, you will be taken to the page you were on previously.

    CONTINUE
    NO THANKS

    TERMS AND CONDITIONS
    Patient Instructions: The ZEGALOGUE® (dasiglucagon) injection Co-Pay Savings Card Program is ONLY valid for patients with commercial (private) insurance. In order to redeem this offer, you must have a valid prescription for ZEGALOGUE and you may not be enrolled in a state or federally funded prescription benefit program, including, but not limited to, Medicare (Parts A, B, C, or D), Medicaid (including Managed Medicaid), Veterans Affairs (VA), Department of Defense (DOD), or TRICARE. You are responsible for the first $25 and the card pays the remainder per prescription, up to a maximum of 12 fills per calendar year. Follow instructions provided by your doctor. This offer may not be redeemed for cash. By using this offer, you are certifying that you meet the eligibility criteria and will comply with the terms and conditions described in the Restrictions section below, including that you will not seek reimbursement for any part of the benefit received through this offer from any third-party payer, including any health savings, flexible spending, or other healthcare reimbursement account. Patients with questions about the offer should call 1-877-501-ZEGA (9342). THIS OFFER IS NOT INSURANCE.

    Pharmacist: As a condition of payment, when you apply this offer, you are certifying that you have not submitted a claim for reimbursement under any federal, state, or other governmental programs including, without limitation, Medicare, Medicaid, VA, DOD, TRICARE, for this prescription and will not seek reimbursement from health insurance or any third party for any part of the benefit the patient receives through this program. Participation in this program must comply with all applicable laws and regulations as a pharmacy provider. By participating in this program, you are certifying that you will comply with the terms and conditions described in the Restrictions section below.

    Pharmacist Instructions for a Patient With an Eligible Third-Party Payer: Submit the claim to the primary Third-Party Payer first, then submit the balance due to CHANGE HEALTHCARE as a Secondary Payer COB (coordination of benefits) with patient responsibility amount and a valid Other Coverage Code, (e.g., 8). The patient is responsible for the first $25 and the card pays the remainder per prescription, up to 12 fills per calendar year. Reimbursement will be received from CHANGE HEALTHCARE.

    A valid Other Coverage Code is required. For any questions regarding CHANGE HEALTHCARE online processing, please call the Help Desk at 1-800-422-5604.

    Restrictions: This offer is valid in the United States. This offer is not valid for prescriptions reimbursed under Medicaid, a Medicare drug benefit plan, VA, DOD, or TRICARE, or other federal or state health programs (such as medical assistance programs). If the patient is eligible for drug benefits under any such program or is Medicare-eligible and enrolled in employer-sponsored group waiver health plans or government-subsidized prescription drug benefit programs for retirees, the patient cannot use this offer. By using this offer, the patient and pharmacist certify that they will comply with any terms or requirements imposed on patients or providers by the health insurance to notify the health insurance plan of the existence and/or value of this offer. This offer is not valid for patients under 6 years of age. It is illegal to (or offer to) sell, purchase, or trade this offer. This offer is not transferable and is limited to one offer per person. Not valid if reproduced. Void where prohibited by law. This is not insurance. Program managed by ConnectiveRx on behalf of Zealand Pharma. The parties reserve the right to rescind, revoke, or amend this offer without notice at any time.

    ZEGALOGUE® vertical logo

    Please select the quantity of co-pay savings cards you would like to download for your eligible patients. 

    Each card has a unique ID number.
    Please do not make copies.
    Downloading may take a few seconds.

    CANCEL
    NEXT